ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record
NCT03397433 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9673
Last updated 2020-08-27
Summary
Beginning in the mid-to late 1980s and accelerating through the 1990s and 2000s the shield of antibiotic invincibility began to crack sufficiently so that it was apparent to everyone we faced a serious problem. The investigators will demonstrate and expand the use of information technology based on the ingenious weighted-incidence, syndromic, combination antibiogram (WISCA) tool for the widespread use of automated clinician prompts enhancing empiric antibiotic therapy as part of a comprehensive infection control stewardship program that reduces antibiotic resistance. This research program will demonstrate that use of such a tool lowers mortality, improves outcome, lowers antimicrobial resistance and reduces healthcare cost.
Conditions
Interventions
- OTHER
-
Information Technology physician assist
The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
Sponsors & Collaborators
-
Endeavor Health
lead OTHER
Principal Investigators
-
Lance R Peterson, MD · Endeavor Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-15
- Primary Completion
- 2018-07-31
- Completion
- 2019-06-30
Countries
- United States
Study Locations
More Related Trials
-
Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting
NCT03612297 ·Status: UNKNOWN
-
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
NCT00167986 ·Status: COMPLETED
-
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
NCT02070757 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
NCT03894046 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Optimize the Use of New Antibiotics
NCT03941951 ·Status: UNKNOWN ·Phase: NA
-
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT00786305 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
NCT03630081 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Discontinuation of Antibiotic Susceptibility Testing on Enterococcus Faecalis Positive Urine Cultures in Hospitalized Patients: an Impact on Antibiotic Prescriptions? (FaecaCible)
NCT05743192 ·Status: COMPLETED
-
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
NCT05922124 ·Status: RECRUITING ·Phase: PHASE4
-
Use of New Antibiotics in Sweden
NCT05048693 ·Status: COMPLETED
-
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
NCT05248490 ·Status: COMPLETED ·Phase: NA
-
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT05094154 ·Status: COMPLETED ·Phase: PHASE4
-
Reducing Perioperative S. Aureus Transmission Via OR PathTrac
NCT04657185 ·Status: COMPLETED
-
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
NCT06652126 ·Status: RECRUITING
-
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
NCT05088421 ·Status: COMPLETED ·Phase: PHASE1
-
Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 9 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD).
NCT03481569 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
NCT00691587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
NCT05171257 ·Status: COMPLETED
-
Resistant Bacteria in Children in France
NCT06036628 ·Status: COMPLETED
-
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
NCT02809131 ·Status: COMPLETED ·Phase: PHASE3
-
Early Oral Switch for Uncomplicated Gram-negative Bacteraemia
NCT05199324 ·Status: RECRUITING ·Phase: PHASE4
-
PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship
NCT05486130 ·Status: UNKNOWN
-
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
NCT01597973 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
NCT05645757 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
NCT07202377 ·Status: NOT_YET_RECRUITING ·Phase: NA